Clinical trials: Prostate Carcinoma
Prostate Cancer
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects…
- Trial name
- NCT03995888
- Testing
- rhPSMA-7.3 (18F) Injection
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00936390
- Testing
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy
- Where
- 518 sites in United States, Canada
- Volunteers
- 1,538 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen…
- Trial name
- STRIVE (NCT01664923)
- Testing
- Enzalutamide, Bicalutamide
- Where
- 109 sites in United States
- Volunteers
- 396 people
- Sponsor
- Pfizer
Prostate Cancer
Vitamin D in Treating Patients With Prostate Cancer
RATIONALE: Vitamin D may be effective in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying how well 4 different doses of vitamin D works in treating patients with prostate cancer.
- Trial name
- NCT00524680
- Testing
- cholecalciferol
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Roswell Park Cancer Institute
Prostatic Neoplasms
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide.
- Trial name
- NCT06072196
- Testing
- Novel hormonal therapy
- Where
- United States
- Volunteers
- 3,017 people
- Sponsor
- Pfizer
Prostate Cancer, Adenocarcinoma of the Prostate
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical…
- Trial name
- NCT00321646
- Testing
- Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mary-Ellen Taplin, MD
Prostate Cancer
Early Changes In Multiparametric MRI In Prostate Cancer
In this research study, the investigators are trying to determine if there are measurable changes in prostate MRI that will help predict those who will or will not respond to Androgen Deprivation Therapy (ADT) and External Beam…
- Trial name
- NCT01959542
- Testing
- MRI, PSA Blood Test
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Prostate Cancer
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal…
- Trial name
- NCT00887458
- Testing
- Itraconazole 200 mg, Itraconazole 300mg
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Johns Hopkins University
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00118092
- Testing
- tanespimycin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT03448458
- Testing
- CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Prostate Cancer
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose…
- Trial name
- NCT02494921
- Testing
- Docetaxel-PNP, Ribociclib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill).
- Trial name
- NCT00090363
- Testing
- ZD4054 15 mg, ZD4054 10 mg
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Prostate Cancer
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
The overall objective of this Early Phase Clinical Trial is to begin defining the accuracy of 68Ga-PSMA-11 for detecting the location and size of clinically significant prostate cancer lesions in low and intermediate risk…
- Trial name
- NCT03429244
- Testing
- 68Ga-PSMA-11 PET-MRI
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Prostate Cancers
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
The purpose of this research project is to test if a compound (chemical substance) has a natural tendency to go to prostate cancer. This compound has a small amount of radioactivity attached to it and is called a radiotracer.
- Trial name
- NCT00917865
- Testing
- anti [18F]FACBC
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- David M. Schuster, MD
Hormone Refractory Prostate Cancer
Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory)…
- Trial name
- NCT00928252
- Testing
- IV fluorine-18 labeled methylcholine before PET/CT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Queen's Medical Center
Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma.
- Trial name
- NCT00582556
- Testing
- Zometa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
High Resolution PET-MRI Before Prostate Cancer HIFU
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-fluciclovine PET-MRI) will detect prostate cancers not seen on standard multiparametric…
- Trial name
- NCT03263780
- Testing
- 18F-Fluciclovine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Timothy J. Daskivich
Prostate Cancer
Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of…
- Trial name
- NCT01607879
- Testing
- Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.